Program
sovateltide
Also written as “Sovateltide”, “SPI-1620” and “PMZ-1620 along with standard treatment”.
Its studies are mostly in Stroke · Ischemic Stroke · Brain Injuries, Traumatic · Hypoxia-Ischemia, Brain · Spinal Cord Injuries, led by 2 companies.
Drug pageSovateltide: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharmazzits history only | 85 open or running | phase 4since Jul 5, 2023 | Jul 31, 2019 | Nov 2026phase 2 · NCT05514340 |
| Zydus Lifesciences | 30 open or running | phase 2since Nov 27, 2012 | Jan 31, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Zydus Lifesciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 31, 2008First study: phase 1 study in CarcinomaFirst studyNCT00613691 · 36 enrolled · United States
- Nov 27, 2012Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01741155 · 34 enrolled · United States
- Jan 14, 2013Phase 2 study in Biliary Tract NeoplasmsNCT01773785 · 30 enrolled · United States
- Jun 9, 2019Named sovateltideINNProposed as its International Nonproprietary Name in WHO's List 121 · before, SPI-1620
TargetBeta
“Sovateltide (PMZ-1620, IRL-1620) is a highly selective ETB receptor agonist and a synthetic analog of ET-1.”study text, by rule · the study
Studies
All 3 Zydus Lifesciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01773785Biliary Tract Neoplasms · United States | 2 | Terminated | Sep 2015 | 30 |
| NCT01741155Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Jul 2015 | 34 |
| NCT00613691Carcinoma · United States | 1 | Completed | Jan 2012 | 36 |
How it is read
Names in the registry
- “Sovateltide”, 3 entries
- “SPI-1620”, 3 entries
- “PMZ-1620 along with standard treatment”, 2 entries
- “PMZ-1620 (sovateltide) along with standard treatment”, 2 entries
- “Sovateltide along with standard treatment”, 1 entry
Conditions, from the studies’ own filings
- Stroke, 2 studies
- Ischemic Stroke, 1 study
- Brain Injuries, Traumatic, 1 study
- Hypoxia-Ischemia, Brain, 1 study
- Spinal Cord Injuries, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.